Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-05-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancercelltransplantradiationchemotherapy
  Phrases that lowered it: participantscombinationulnmgcount
• Sponsor's past termination rate: 20.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 17.1% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 58 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 191039 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 435 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.3% (raises risk) · Drug's FDA history
• Design: sequential (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 22010 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 5 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer NCT06145412 · started 2023 · scored riskier than 84% of active trials completed
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) NCT05386550 · started 2022 · scored riskier than 92% of active trials terminated
• Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma NCT05724602 · started 2023 · scored riskier than 98% of active trials terminated
• Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer NCT05930938 · started 2023 · scored riskier than 85% of active trials terminated
• Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary NCT00873119 · started 2009 · scored riskier than 82% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.